A Study of Patients Receiving High-Dose Rate Brachytherapy
Number: NCT00924027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
Number: NCT01581749
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Albert DeNittis|Main Line Health
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
Number: NCT02362451
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Number: NCT02643667
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Washington University School of Medicine|Pharmacyclics LLC.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Specialized radiation therapy for Treating Patients With Prostate Cancer
Number: NCT03367702
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
To learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy
Number: NCT03424850
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Washington University School of Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Number: NCT03429244
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Indiana University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Number: NCT03496805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
Number: NCT03525262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Texas Southwestern Medical Center|Boston Scientific Corporation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Rucaparib in Nonmetastatic Prostate Cancer Patients with Genetic Mutations
Number: NCT03533946
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Number: NCT03572387
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance
Number: NCT03679260
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Number: NCT03716739
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|National Institute on Aging (NIA)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Number: NCT03735680
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OncoNano Medicine, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Number: NCT03769766
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): University of Texas Southwestern Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Number: NCT03809078
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy
Number: NCT03821246
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Lawrence Fong|Genentech, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2| Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Number: NCT03860987
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
Number: NCT03933670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
Number: NCT04147806
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Albert Einstein College of Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s) |
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Number: NCT04264208
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrei Iagaru|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
Number: NCT04300855
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Number: NCT04373564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Guerbet|Bayer AG (Sponsor)|Bracco (Sponsor)|GEHC (Sponsor)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Number: NCT04461509
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alessandro D'Agnolo|Progenics Pharmaceuticals, Inc.|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Number: NCT04530552
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC
Number: NCT04720157
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Novartis Pharmaceuticals|Alliance Foundation Trials, LLC.|RTOG Foundation, Inc.|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |